Physician profile
Kevin Rapeport
NPI 1952308124
$10,359.05
in general payments reported to CMS, 2019-2025
49 companies · $1,012 in 2025
The $1,012 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,753 · 2020: $1,394 · 2021: $1,800 · 2022: $1,534 · 2023: $1,568 · 2024: $1,298 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,684.06 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,162.23 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $821.62 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Janssen Pharmaceuticals, INC | $682.18 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $651.41 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Pfizer INC. | $574.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $356.82 | 2019-2024 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $347.16 | 2021-2025 | Eliquis, Camzyos |
| Kowa Pharmaceuticals America, INC. | $293.29 | 2020-2023 | Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.43 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $289.52 | 2019-2025 | Watchman Flx, Watchman Access System |
| Cvrx, INC. | $240.00 | 2021-2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $234.15 | 2020-2024 | Nexletol |
| Novo Nordisk INC | $206.83 | 2021-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $206.50 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Rapeport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.